These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model. van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347 [TBL] [Abstract][Full Text] [Related]
29. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548 [TBL] [Abstract][Full Text] [Related]
30. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. Wong YC; Holzbaur EL J Neurosci; 2014 Jan; 34(4):1293-305. PubMed ID: 24453320 [TBL] [Abstract][Full Text] [Related]
31. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655 [TBL] [Abstract][Full Text] [Related]
32. Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production. Formisano S; Hornig M; Yaddanapudi K; Vasishtha M; Parsons LH; Briese T; Lipkin WI; Williams BL J Virol; 2017 Jul; 91(14):. PubMed ID: 28446679 [TBL] [Abstract][Full Text] [Related]
34. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Rodrigues FB; Byrne LM; Lowe AJ; Tortelli R; Heins M; Flik G; Johnson EB; De Vita E; Scahill RI; Giorgini F; Wild EJ J Neurochem; 2021 Jul; 158(2):539-553. PubMed ID: 33797782 [TBL] [Abstract][Full Text] [Related]
35. Tryptophan metabolites and brain disorders. Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508 [TBL] [Abstract][Full Text] [Related]
36. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Wang CE; Tydlacka S; Orr AL; Yang SH; Graham RK; Hayden MR; Li S; Chan AW; Li XJ Hum Mol Genet; 2008 Sep; 17(17):2738-51. PubMed ID: 18558632 [TBL] [Abstract][Full Text] [Related]
37. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. Beal MF; Matson WR; Swartz KJ; Gamache PH; Bird ED J Neurochem; 1990 Oct; 55(4):1327-39. PubMed ID: 2144582 [TBL] [Abstract][Full Text] [Related]
38. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558 [TBL] [Abstract][Full Text] [Related]
39. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. Luo S; Vacher C; Davies JE; Rubinsztein DC J Cell Biol; 2005 May; 169(4):647-56. PubMed ID: 15911879 [TBL] [Abstract][Full Text] [Related]
40. Analysis of mutant and total huntingtin expression in Huntington's disease murine models. Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]